Latest Press Releases
![Royal Biologics Launches Amnio-Maxx™, an Extracellular Matrix Product Derived From Human Amniotic Placental Tissue](https://cdn.nwe.io/files/x/a8/89/0b861c83c2b4146bd3a14b4d7c7e.jpg)
FEATURED
50% Commission Offering for Initial Distributors. Amnio-Maxx™ will be used to treat various conditions in orthopedics and sports medicine.
BIOINCYTE™ is a Next-Generation Autologous Fibrin and Platelet System
![Royal Biologics Announces FDA 510K Approval and U.S. Commercial Launch of the MAXX™-BMC Bone Marrow Aspirate Concentration System](https://cdn.nwe.io/files/x/86/06/246403c5b203918b6c05cb9bfbd2.jpg)
![Royal Biologics Announces U.S. Commercial Launch of Advanced-Cell™, an Advanced Bone Grafting and Fusion Convenience Kit](https://cdn.nwe.io/files/x/bb/1a/1cf4314c6c3e5f846be47d6ed54b.jpg)
![Royal Biologics Announces Partnership With Vilex Launching Its ALC Technology Into Lower Extremity Industry](https://cdn.nwe.io/files/x/94/c1/c2a98b6166a332703be2c587511a.jpg)
Royal Biologics' Cryo-Cord™, Amnio-Maxx™, Amnio-Maxx™ Lite and Derm-Maxx™ Receive High-Tier Reimbursement in the Hospital Outpatient Departments and Reimbursement in the Physician Office to Treat Chronic Non-Healing Wounds
![Royal Biologics Announces the Launch of Fibri-Cell™, Live Cellular Cortical Fibers With Osteo-Spin™ Technology](https://cdn.nwe.io/files/x/ea/e6/efebc63ae75c46b53c6d3180f620.jpg)
The acquisition of the FIBRINET system adds new novel technology to Royal Biologics' growing portfolio of Autologous Live Cell solutions